News | January 22, 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Hitz shall assume new role from January 17th, 2022
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Home Healthcare market is expected to be US $ 14.2 by 2025
Subscribe To Our Newsletter & Stay Updated
